Ligand Pharmaceuticals (LGND) Profit After Tax Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ligand Pharmaceuticals | 4.55 Bn | 3.77 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.31% |
| Dec 31, 2025 | 50.70% |
| Sep 30, 2025 | 81.14% |
| Jun 30, 2025 | -26.16% |
| Mar 31, 2025 | -11.96% |
| Dec 31, 2024 | -33.38% |
| Sep 30, 2024 | 14.01% |
| Jun 30, 2024 | -29.20% |
| Mar 31, 2024 | -33.58% |
| Dec 31, 2023 | 19.80% |
| Sep 30, 2023 | -16.57% |
| Jun 30, 2023 | -49.98% |
| Mar 31, 2023 | -1.52% |
| Dec 31, 2022 | 16.27% |
| Sep 30, 2022 | -64.06% |
| Jun 30, 2022 | -15.01% |
| Mar 31, 2022 | -18.53% |
| Dec 31, 2021 | -11.63% |
| Sep 30, 2021 | 80.86% |
| Jun 30, 2021 | 47.49% |
| Mar 31, 2021 | 22.34% |
| Dec 31, 2020 | -1.90% |
| Sep 30, 2020 | -15.25% |
| Jun 30, 2020 | 0.05% |
| Mar 31, 2020 | -102.44% |
| Dec 31, 2019 | -24.94% |
| Sep 30, 2019 | -69.32% |
| Jun 30, 2019 | -61.71% |
| Mar 31, 2019 | 216.53% |
| Dec 31, 2018 | -89.95% |
| Sep 30, 2018 | 102.77% |
| Jun 30, 2018 | 64.41% |
| Mar 31, 2018 | 103.29% |
| Dec 31, 2017 | -79.10% |
| Sep 30, 2017 | 222.57% |
| Jun 30, 2017 | 80.02% |
| Mar 31, 2017 | 109.09% |
| Dec 31, 2016 | -21.67% |
| Sep 30, 2016 | 17.62% |
| Jun 30, 2016 | -71.00% |
| Mar 31, 2016 | -7.25% |
| Dec 31, 2015 | 5.90% |
| Sep 30, 2015 | 79.85% |
| Jun 30, 2015 | 138.98% |